Fibroblast activation protein (FAP) is absent or expressed at a very low level in normal tissues. However, it is overexpressed in around 80% of solid tumor stroma.
Rakovina Therapeutics Inc. has obtained a short-list of recommended drug candidates from an initial artificial intelligence (AI) screening effort using the Deep Docking AI platform under a collaboration with the University of British Columbia.
At the European Association of Nuclear Medicine meeting, Monopar Therapeutics Inc. presented the preclinical characterization of MNPR-101, a first-in-class urokinase-type plasminogen activator receptor (uPAR)-targeting radiopharmaceutical agent with high stability in vivo and more than 1 week of shelf-life in its labeled form, [177Lu]-MNPR-101.
FMS‐like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase validated as a therapeutic target for acute myeloid leukemia (AML) and regarded as an indicator of poor prognosis. Unfortunately, current FLT3 inhibitors, such as midostaurin, quizartinib or gilteritinib, often lead to myelosuppression or cardiovascular toxicity.
Scientists from different laboratories around the world have presented the latest advances in research into malignant brain tumors at the 31st Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), which is being held Oct. 22 to 25 in Rome.
The combination of radiotherapy with immune checkpoint blockade shows promise for synergistic cancer therapy efficacy. LNC-1004 is a vector targeting fibroblast activation protein (FAP) conjugated with Evans Blue for enhanced tumor uptake and retention. Xiamen University and the National University of Singapore have presented data regarding the [177Lu]LNC-1004 radiopharmaceutical in combination with anti-PD-L1 therapy for the treatment of pan-cancers.
Aposense Ltd. has prepared and tested peptide-drug conjugates comprising a cell-penetrating peptide covalently bound to the therapeutically affective amino acid sequence (SAPK1 [JNK] inhibitors) linked to sterol derivatives through a linker reported to be useful for the treatment of cancer.
A patent from Nanjing Mingde New Drug Research Co. Ltd. and Zhangzhou Pientzehuang Pharmaceutical Co. Ltd. details the identification of salts of interleukin-1 receptor-associated kinase 4 (IRAK-4) degradation inducers reported to be useful for the treatment of diffuse large B-cell lymphoma.
RSS
